Revolution Medicines, Inc., a late-stage clinical oncology company, has updated clinical data from two Phase 1/2 trials of its lead investigational candidate, Daraxonrasib, in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). The firm stated that these findings support DaraxONrasib's continued evaluation in the first-line setting, demonstrating manageable safety and tolerability profiles and early signs of durable antitumor activity across monotherapy and combination approaches. The company's pipeline includes RAS(ON) inhibitors designed to suppress diverse oncogenic RAS variants. DaraxOnrasib (RMC-6236), Elironrasib and Zoldonraib, all currently in clinical development, being evaluated in four global Phase 3 clinical trials. As of a December 1, 2025 data cutoff, 40 patients with PDAC received darraxib 200 mg once daily in 28-day cycles, plus gemcitabine and nab-paclitaxel (GnP), given on a Day 1 and Day 15 schedule.